Document is current
Any future updates will be listed below
-
Authors
Mizuno, Kei
Ku, Sheng-Yu https://orcid.org/0000-0003-4715-1888
Venkadakrishnan, Varadha Balaji https://orcid.org/0000-0001-7071-4584
Bakht, Martin K. https://orcid.org/0000-0001-8803-2485
Sigouros, Michael https://orcid.org/0000-0002-0328-8359
Chan, Joanna
Trigos, Anna https://orcid.org/0000-0002-5915-2952
Driskill, Jordan H. https://orcid.org/0000-0003-4319-3845
Manohar, Jyothi
King, Abigail https://orcid.org/0009-0008-5358-8414
Presser, Adam G.
Kim, Min Jin
Tewari, Alok K. https://orcid.org/0000-0003-2617-7499
Long, Henry W. https://orcid.org/0000-0001-6849-6629
Quigley, David https://orcid.org/0000-0002-4726-1473
Choueiri, Toni K. https://orcid.org/0000-0002-9201-3217
Balk, Steven https://orcid.org/0000-0002-4546-7371
Hill, Sarah https://orcid.org/0000-0002-9199-9459
Mosquera, Juan Miguel https://orcid.org/0000-0003-4666-6476
Einstein, David
Sandhu, Shahneen https://orcid.org/0000-0002-8660-4475
Taplin, Mary-Ellen
Beltran, Himisha https://orcid.org/0000-0003-3259-2226
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R37CA241486-01A1, P50 CA272390-0)
U.S. Department of Defense (HT94252310407, W81XWH-17-1-0653)
Prostate Cancer Foundation
- License Information
-
More Information
Article History
Received: 5 February 2025
Accepted: 30 May 2025
First Online: 1 July 2025
Competing interests
: T.K.C reports institutional and/or personal, paid and/or unpaid support for research, advisory boards, consultancy, and/or honoraria past 10 years, ongoing or not, from Alkermes, Arcus Bio, AstraZeneca, Aravive, Aveo, Bayer, Bristol Myers-Squibb, Bicycle Therapeutics, Calithera, Circle Pharma, Deciphera Pharmaceuticals, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, Gilead, HiberCell, IQVA, Infinity, Institut Servier, Ipsen, Jansen, Kanaph, Lilly, Merck, Nikang, Neomorph, Nuscan/PrecedeBio, Novartis, Oncohost, Pfizer, Roche, Sanofi/Aventis, Scholar Rock, Surface Oncology, Takeda, Tempest, Up-To-Date, CME and non-CME events (Mashup Media Peerview, OncLive, MJH, CCO), for work unrelated to the present study. A.K.T. reports institutional research funding from Novartis for work unrelated to the present study. D.E. reports institutional research funding and honoraria from Bayer, Bristol-Myers Squibb, Cardiff Oncology, MiNK Therapeutics, Novartis, Puma Biotechnology, Sanofi, Nimbus Therapeutics, Foundation Medicine, for work unrelated to the present study. S.S. has served as a consultant advisor for Bristol Myers Squibb, Merck Sharp and Dohme, AstraZeneca, Novartis, Janssen and Merck Serono (funds go to the institution) and received research grants for investigator-initiated trials from Novartis, Genentech, Amgen, AstraZeneca, Merck Serono, Merck Sharp and Dohme, Pfizer and Senwha (funds go to the institution) for work unrelated to the present study. H.B. has served as consultant/advisory board member for Astra Zeneca, Merck, Pfizer, Amgen, Novartis, Bayer, Daiichi Sankyo, and has received research funding (to institution) from Janssen, Bristol Myers Squibb, Circle Pharma, Daiichi Sankyo, Novartis for work unrelated to the present study. The remaining authors declare no competing interests.
